Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Airs Phase III Data For Weekly GLP-1 Albiglutide, Plans To File By Year-End

This article was originally published in The Pink Sheet Daily

Executive Summary

GSK/Human Genome Sciences’ once-weekly injectable GLP-1 agonist albiglutide succeeds in a non-inferiority study and should be filed in late 2012. But analysts critique efficacy relative to the competition and some say the diabetes drug will come to the market too late.

Advertisement

Related Content

GSK Highlights Easy Pen Delivery Of Albiglutide As FDA Begins Review
GSK Highlights Easy Pen Delivery Of Albiglutide As FDA Begins Review
With Bristol/AstraZeneca In Driver’s Seat, GLP-1 Race Takes A Turn
Diabetes Leaders Lilly, Sanofi Give A Glimpse Of GLP-1 Strategy
GSK’s Bid For Human Genome Sciences: A Deal Decades In The Making
Riding High, Victoza Hopes To Gain Ground Over Popular DPP-4s With Label Change
Weeks After Bydureon Launch, Amylin Looks Like A Takeout Target
Amylin’s Bydureon Approval: How Does It Sit With Novo Nordisk?
Failed Head-To-Head Study Clouds Bydureon's Commercial Future

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS073967

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel